Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M-CENK and N-803 with Gemcitabine in Platinum-Resistant High-Grade Ovarian Cancer
NCT06710288Phase 2Recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Nov 2024
- Primary completion
- May 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of M-CENK, nogapendekin alfa inbakicept in ovarian cancer, sponsored by ImmunityBio, Inc.. Started Nov 2024; status: recruiting.
02
Drugs
M-CENKnogapendekin alfa inbakicept
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06710288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06710288.